Feature | February 01, 2012| Dave Fornell

Cardiac Technology Trend Predictions for 2012

Based on my observations and those of the doctors on the Diagnostic & Interventional Cardiology Editorial Advisory Board, we created the following list of predictions of what will be hot trends to watch in 2012.


•  FFR-CT: A potential “game-changer” technology that was recently introduced is fractional flow reserve computed tomography (FFR-CT), which  computationally models coronary blood flow, pressure and physiology from static typically acquired by CT scans.  The information may be able to determine if a specific stenosis needs to be stented without the need for invasive, catheter FFR measurements in the cath lab.


•  Transcatheter Heart Valves: With the U.S. Food and Drug Administration (FDA) clearance of the Edwards Sapien valve (see story on Page 34), transcatheter aortic valve implantation (TAVI) is taking center stage at several conferences. Also in FDA trials are Medtronic’s CoreValve aortic valve and Abbott’s MitraClip device for mitral valve repair.


• Percutaneous Renal Nerve Ablation: Medtronic purchased Ardian, which developed the Symplicity renal nerve ablation catheter currently in FDA trial. Data so far has shown the therapy may greatly reduce drug-resistant hypertension.


• Left Atrial Appendage (LAA) Occluders:  These transcatheter occluders are designed to prevent atrial fibrillation-induced emboli and replace the current standard of warfarin therapy. In 2011 the CoHerex WaveCrest entered first-in-man trials and Boston Scientific purchased Atritech’s Watchman LAA occluder.


• Drug-Eluting Balloons: Several DEBs are already available in Europe and several vendors are seeking FDA clearance. Lutonix (purchased by C.R. Bard in December) has an ongoing FDA trial. Medrad, Cook and Medtronic/Invatec are working with the FDA to begin U.S. trials.


• Hybrid Operating Rooms: While hybrid ORs are not a new concept, the approval of the first transcatheter aortic valve and increasingly more complex minimally invasive surgeries and interventional procedures are driving their adoption. Vendors are increasingly emphasizing the hybrid OR applications of their products due to rising interest.


• Robotics in the Cath Lab: The Corindus CorPath 200 cath lab robotic system entered its FDA pivotal clinical trial with possible final review in 2012. Boston Scientific and Philips both partnered with robotic system vendors for closer integration. Hansen Medical is also developing a peripheral artery disease interventional robotic system it hopes will be reviewed in 2012 by the FDA. See the story on Page 8.


I am always interested in hearing readers’ thoughts on technologies or trial data from the past year, or in their predictions for what technologies to watch in the coming year.

Related Content

transcatheter repair of a mitral valve paravalvular leak

Transcatheter repair of a surgical mitral replacement paravalvular leak with an Amplatzer Vascular Plug II.

Feature | Heart Valve Repair| February 08, 2016 | Dave Fornell
Off-label use of the St.
Stereotaxis, Philips, collaboration, Niobe ES remote magnetic navigation system, Allura Xper FD10 cardiovascular X-ray

Niobe ES image courtesy of Stereotaxis Inc.

Technology | Cath Lab| February 04, 2016
February 4, 2016 — Stereotaxis and Philips have signed an addendum pursuant to their existing Development and Coopera
medtronic corevalve, tavr
News | February 03, 2016 | Dave Fornell
Medtronic announced Feb. 3 that the U.S.
Cook Medical Zenith Alpha Thoracic Endovascular Graft, first U.S. patient, Cleveland Clinic
News | Stent Grafts| January 28, 2016
In November, following the U.S. Food and Drug Administration approval of Cook Medical’s Zenith Alpha Thoracic...
Toshiba, CT-angiography, hybrid OR

Toshiba recently introduced a new line of combined CT and angiography systems, allowing true CT imaging on demand in the interventional lab.

Feature | Angiography| January 27, 2016 | Dave Fornell
All of the major vendors in the United States introduced new systems and technologies in the past few years to reduce...
Sponsored Content | Case Study | Cardiovascular Ultrasound| January 21, 2016
This case study is from the Cardiac Imaging Department, Hospital Clinic, Barcelona, Spain.
AVR, aortic valve replacement, middle-aged patients, University of Sydney study, metal, tissue
News | Heart Valve Repair| January 15, 2016
Patients between the ages of 40 and 70 who undergo aortic valve replacement (AVR) may fare better with tissue-based...
Sapien III, Sapien 3, PARTNER III

The Edwards Sapien 3 valve uses a skirt at its base to prevent paravalvular leak. This is the newest version of the Sapien and will be used in the upcoming PARTNER III Trial.

Feature | Heart Valve Repair| January 15, 2016 | Dave Fornell
January 15, 2016 — The U.S.
heart valve formation, newborns, congenital heart defects, Cornell study
News | Congenital Heart| January 14, 2016
January 14, 2016 — Cornell biomedical engineers have discovered natural triggers that could reduce the chance of life
Corindus, MGH, Massachusetts General, CorPath System, robotic-assisted coronary intervention program
News | Robotic Systems| January 06, 2016
Corindus Vascular Robotics Inc. announced the launch of a CorPath robotic-assisted coronary intervention program at...
Overlay Init